Caisse DE Depot ET Placement DU Quebec Has $12.66 Million Stock Holdings in Hologic, Inc. $HOLX

Key Points

• Caisse DE Depot ET Placement DU Quebec increased its holdings in Hologic, Inc. by 17.2% in the first quarter, owning approximately $12.7 million worth of shares.
• Multiple analysts have raised their price targets for Hologic, with Royal Bank of Canada setting a new target of $87.00 and Argus assigning an $80.00 price target while upgrading the stock to a "buy" rating.
• Hologic's latest quarterly earnings showed an earnings per share (EPS) of $1.08, exceeding expectations, with revenue growth of 1.2% year-over-year amounting to $1.02 billion.

Caisse DE Depot ET Placement DU Quebec lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 17.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 204,887 shares of the medical equipment provider's stock after buying an additional 30,128 shares during the period. Caisse DE Depot ET Placement DU Quebec owned approximately 0.09% of Hologic worth $12,656,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Beverly Hills Private Wealth LLC boosted its position in shares of Hologic by 3.6% during the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after buying an additional 180 shares during the period. Allworth Financial LP boosted its position in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after buying an additional 216 shares during the period. Dark Forest Capital Management LP boosted its position in shares of Hologic by 7.9% during the fourth quarter. Dark Forest Capital Management LP now owns 3,053 shares of the medical equipment provider's stock worth $220,000 after buying an additional 223 shares during the period. Baker Avenue Asset Management LP boosted its position in shares of Hologic by 0.5% during the fourth quarter. Baker Avenue Asset Management LP now owns 42,051 shares of the medical equipment provider's stock worth $3,031,000 after buying an additional 225 shares during the period. Finally, Integrated Advisors Network LLC boosted its position in shares of Hologic by 5.4% during the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider's stock worth $346,000 after buying an additional 289 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Up 0.8%

Shares of HOLX traded up $0.50 during mid-day trading on Monday, reaching $67.12. The company's stock had a trading volume of 1,080,191 shares, compared to its average volume of 1,681,669. The business has a fifty day moving average of $66.15 and a 200 day moving average of $62.49. The company has a market cap of $14.93 billion, a price-to-earnings ratio of 27.85, a price-to-earnings-growth ratio of 2.44 and a beta of 0.57. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

HOLX has been the subject of a number of research analyst reports. Morgan Stanley upped their target price on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. UBS Group upped their target price on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and upped their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. Argus upgraded Hologic from a "hold" rating to a "buy" rating and set a $80.00 target price for the company in a research report on Monday, August 18th. Finally, Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, Hologic currently has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.